Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma

被引：0

作者：

S Yamasaki

R Suzuki

K Hatano

K Fukushima

H Iida

S Morishima

Y Suehiro

T Fukuda

N Uchida

H Uchiyama

H Ikeda

A Yokota

K Tsukasaki

H Yamaguchi

J Kuroda

H Nakamae

Y Adachi

K-i Matsuoka

Y Nakamura

Y Atsuta

J Suzumiya

机构：

[1] National Hospital Organization Kyushu Medical Center,Department of Hematology and Clinical Research Institute

[2] Shimane University Hospital,Department of Oncology and Haematology

[3] Jichi Medical University,Division of Hematology and Cell Therapy

[4] Rinku General Medical Center,Division of Hematology

[5] National Hospital Organization Nagoya Medical Center,Division of Cell Therapy

[6] Fujita Health University School of Medicine,Department of Hematology and Oncology

[7] National Hospital Organization Kyushu Cancer Center,Department of Hematology

[8] National Cancer Center Hospital,Division of Hematopoietic Stem Cell Transplantation

[9] Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital,Department of Hematology

[10] Japanese Red Cross Kyoto Daiichi Hospital,Department of Hematology

[11] Rheumatology and Clinical Immunology,Department of Gastroenterology

[12] Sapporo Medical University Hospital,Department of Hematology

[13] Chiba Aoba Municipal Hospital,Hematology Division

[14] National Cancer Center Hospital East,Department of Hematology

[15] Nippon Medical School,Division of Hematology and Oncology, Department of Medicine

[16] Kyoto Prefectural University of Medicine,Department of Hematology

[17] Osaka City University Hospital,Department of Internal Medicine

[18] Japan Community Health Care Organization Kobe Central Hospital,Division of Hematology and Oncology

[19] Okayama University Hospital,Third Department of Internal of Medicine

[20] Yamaguchi University School of Medicine,Department of Healthcare Administration

[21] Nagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell Transplantation,undefined

来源：

Bone Marrow Transplantation | 2017年 / 52卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.

引用

页码：969 / 976

页数：7

共 122 条

[1]

Milligan DW(1999)Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation Br J Haematol. 106 1020-1026

[2]

Ruiz De Elvira MC(1998)Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease Blood 92 1933-1940

[3]

Kolb HJ(1991)Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease J Clin Oncol. 9 1575-1579

[4]

Goldstone AH(1998)Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study Blood 91 4496-4503

[5]

Meloni G(2007)Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant. 39 59-70

[6]

Rohatiner AZ(2012)Acute myeloid leukemia developing in patients with autoimmune diseases Haematologica 97 805-817

[7]

André M(2007)Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System Int J Hematol. 86 269-274

[8]

Henry-Amar M(2016)Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data) Int J Hematol. 103 3-10

[9]

Blaise D(2012)A disease risk index for patients undergoing allogeneic stem cell transplantation Blood 120 905-913

[10]

Colombat P(2013)Investigation of the freely available easy-to-use software 'EZR' for medical statistics Bone Marrow Transplant. 48 452-458

← 1 2 3 4 5 6 7 8 9 10 →